Idenix Pharmaceuticals (IDIX)

[DewDiligence]

IDIX ReadMeFirst

[Updates: 2008 news flow (including CROI conference),
musings on valuation and the size of an HIV partnership,
upgrade from Susquehanna, IDIX vs VRUS comparison,
and HIV compound from RDEA.]


What is IDIX’s business all about?
#msg-25836900 Capsule and detailed descriptions
#msg-23279256 Addressable markets for antiviral drugs
#msg-25835562 Drug portfolio
#msg-24373864 Transcript of 3Q07 CC
#msg-25841903 IDIX is back in the HCV arena!


Valuation and finances
#msg-25899731 What’s not to like?
#msg-25922668 Upgrade from Susquehanna (1/11/08)
#msg-22707854 Valuation is cheap!
#msg-25870940 IDIX vs VRUS
#msg-24329296 3Q07 financial results


Upcoming events
#msg-25841812 2008 news flow
#msg-25940920 Events at CROI conference in February


Officers, directors, and major shareholders
Capsule résumés of executive officers (click on a name)
Capsule résumés of directors (page 5-6)
Major shareholders
#msg-22707884 Protection from hostile takeover
#msg-11075184 CEO bought shares at $9.13


Development program in HIV
#msg-25836446 IDX899 development program
#msg-25885594 Musings on size of an HIV partnership
#msg-23279256 HIV addressable market
#msg-24139072 Increased HIV screening will expand market
#msg-24673329 HIV competitive landscape
#msg-22596568 Sustiva (the top NNRTI) sells almost $1B/yr
#msg-25102959 IDX899 seeks to supersede Sustiva
#msg-24329960 IDX899 has no cross-resistance to Sustiva
#msg-23282517 Competing early-stage NNRTI’s
#msg-20997326 Phase-3 data for TMC125 (JNJ)
#msg-21895680 Importance of once-daily dosing
#msg-22980439 Pfizer
#msg-25649546 RDEA


Development program in HCV
#msg-25841903 IDIX is back in the HCV arena!
#msg-25802238 IDX184 selected as lead candidate
#msg-25836105 How is IDX184 better than NM283?
#msg-25836250 IDX184 much more potent than NM283
#msg-23279256 HCV addressable market
#msg-25836581 HCV news flow in 2008
#msg-23031685 What’s ahead for HCV combination treatment?
#msg-21197309 NM283 development discontinued


Tyzeka/Sebivo commercial program in HBV
#msg-23242360 Restructuring of Tyzeka relationship with NVS
#msg-24405569 Twelve different royalty tiers
#msg-23249593 Conjecture on the royalty rates
#msg-23007328 Global HBV sales to reach $1.5B in 2010
#msg-24374381 US market is expanding rapidly
#msg-22707869 European market is large and poorly penetrated
#msg-23785846 Status of European launch
#msg-23434932 Treating asymptomatic e- patients will boost market
#msg-23007373 Prevalence of HBV by country
#msg-11099728 Asian immigrants are largely untreated
#msg-22771678 Tyzeka sales guidance for 2007
#msg-24330255 3Q07 US-only sales
#msg-21358606 Why a slow sales ramp for new HBV drugs?
#msg-21388028 Bearish opinion by ‘gofishmarko’
#msg-25802364 Tyzeka US weekly scripts
#msg-25806177 Tyzeka vs Baraclude sales ramp


Tyzeka clinical data
#msg-14377860 Two-year data from GLOBE trial
#msg-22771520 Tyzeka studies in progress
#msg-12271882 Tyzeka resistance data
#msg-14404551 Tyzeka’s efficacy comparable to Baraclude’s (1)
#msg-18389527 Tyzeka’s efficacy comparable to Baraclude’s (2)
http://www.fda.gov/cder/foi/label/2006/022011lbl.pdf FDA product label


Competitive landscape in HBV: general
#msg-24374381 Tyzeka competition
#msg-21652956 Prices of HBV drugs


Competitive landscape in HBV: Baraclude
#msg-22555240 Baraclude studies in progress
#msg-21652925 Baraclude’s black-box warning for HIV/HBV co-infection
#msg-21678537 Size of HIV/HBV co-infection market
#msg-21678801 Tyzeka’s edge in pre-menopausal women
#msg-23241377 Three-year Baraclude resistance data
#msg-23991491 Current Baraclude sales
#msg-24004519 Baraclude sales ramp 2005-present


Competitive landscape in HBV: Hepsera
#msg-24374381 Hepsera’s efficacy is inferior to Tyzeka’s
#msg-21460468 Gilead to cease promotion when Viread approved
#msg-23810770 Current Hepsera sales


Competitive landscape in HBV: Viread/Truvada
#msg-24255644 Phase-3 Viread data
#msg-22555241 Viread/Truvada studies in progress
#msg-20250616 Viread is structurally similar to Hepsera


Competitive landscape in HBV: Clevudine
#msg-23309283 Global phase-3 program
#msg-23359068 Musings on sustained virologic response (SVR)
#msg-14328142 Clinical results from Korea
#msg-20250616 Clevudine and Tyzeka are structurally similar (diagram)
#msg-20218516 Clevudine, Tyzeka are structurally similar (commentary)


Educational Links
http://www.cdc.gov/ncidod/diseases/hepatitis/b/fact.htm
http://www.who.int/mediacentre/factsheets/fs204/en
http://www.idenix.com/about/media/Glossary_of_terms.pdf
http://www.idenix.com/hepb/about
http://www.idenix.com/hiv/about
http://www.idenix.com/hepc/about
http://www.hivandhepatitis.com
http://www.hepfi.org